

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

February 20, 2007
Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

State of New York
(State of Other Jurisdiction
of Incorporation)

1-10113
(Commission File Number)

11-0853640
(I.R.S. Employer
Identification Number)

616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Item 8.01**Other Events**

On February 20, 2007, the Registrant drew down the final \$596,000 of a \$2.0 million November, 2006 bridge funding commitment from Essex Woodlands Health Ventures V, L.P., Care Capital Investments II, L.P., Care Capital Offshore Investments II, L.P., Galen Partners III, L.P., Galen Partners International III, L.P. and Galen Employee Fund III, L.P. (the “November Bridge Loan Commitment”). In November and December, 2006 and January, 2007, the Registrant had drawn a total of \$1,404,000 against the November Bridge Loan Commitment. Advances under the November Bridge Loan Commitment bear interest at the rate of 10% per annum, are secured by a lien on all assets of the Registrant and its subsidiary and mature on March 31, 2007. Including the \$596,000 secured on February 20, 2007, the Registrant has a total of \$8.7 million in bridge loans outstanding and due on March 31, 2007.

On February 20, 2007, the Registrant issued the press release attached hereto as Exhibit 99.1 in connection with the above-described drawdown.

Item 9.01**Financial Statements and Exhibits****Exhibit Number****Description**

99.1	Press Release dated February 20, 2007 Announcing Drawdown of Bridge Funding
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter Clemens

Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: February 20, 2007

Exhibit Index

Exhibit Number

Description

99.1	Press Release dated February 20, 2007 Announcing Draw Down of Bridge Funding
------	--

CONTACT: Acura Pharmaceuticals, Inc.,
Investor Relations, Peter A. Clemens, SVP & CFO **847-705-7709**

FOR IMMEDIATE RELEASE

**ACURA PHARMACEUTICALS, INC. COMPLETES DRAW DOWN OF
NOVEMBER, 2006 BRIDGE FUNDING COMMITMENT**

Palatine, IL, February 20, 2007: Acura Pharmaceuticals, Inc. (OTC.BB-ACUR) today announced it has completed the draw down of the \$2.0 million November, 2006 bridge funding commitment from Essex Woodlands Health Ventures V, L.P., Care Capital Investments II, L.P., Care Capital Offshore Investments II, L.P., Galen Partners III, L.P., Galen Partners International III, L.P. and Galen Employee Fund III, L.P. (the “November Bridge Loan Commitment”). In November and December, 2006 and January, 2007, the Company had drawn a total of \$1,404,000 against the November Bridge Loan Commitment. On February 20, 2007 the remainder of \$596,000 under the November Bridge Loan Commitment was received by the Company. Advances under the November Bridge Loan Commitment bear interest at the rate of 10% per annum, are secured by a lien on all assets of the Company and its subsidiary, mature on March 31, 2007 and are senior to all other Company debt. Including the \$596,000 secured today, the Company has a total of \$8.7 million in bridge loans outstanding and due on March 31, 2007.

Cash Reserves

The Company estimates that its current cash reserves will fund operations through mid-to-late March, 2007. To continue operating thereafter, the Company must raise additional financing or enter into appropriate collaboration agreements with third parties providing for cash payments to the Company. No assurance can be given that the Company will be successful in obtaining any such financing or in securing collaborative agreements with third parties on acceptable terms, if at all, or if secured, that such financing or collaborative agreements will provide for payments to the Company sufficient to continue funding operations. In the absence of such financing or third-party collaborative agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, the Company's ability to secure additional financing to fund continued operations, the Company's ability to enter into contractual arrangements with qualified pharmaceutical partners to license, develop and commercialize the Company's technology and product candidates, the Company's ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the Company's ability to fulfill the FDA's requirements for approving the Company's product candidates for commercial distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of the Company's product candidates, the adequacy of the development program for the Company's product candidates, changes in regulatory requirements, adverse safety findings relating to the Company's product candidates, the risk that the FDA may not agree with the Company's analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of the Company's product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process. You are encouraged to review other important risk factors relating to the Company on our web site at www.acurapharm.com under the link, "Company Risk Factors" and detailed in Company filings with the Securities and Exchange Commission. The Company is at development stage and may never have any products or technologies that generate revenue. Acura Pharmaceuticals, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. All Acura Pharmaceuticals, Inc. press releases may be reviewed at www.acurapharm.com.
